Insights from Financial Economics to Value Healthcare Investments that Reduce System-Level Risks: Example of Disease Elimination and Eradication
Open Access
- 22 March 2026
- journal article
- review article
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 24 (3) , 449-458
Abstract
System-level risks generate volatility that can threaten the stability of public health systems and jeopardise population health. In financial terms, these risks may be systematic, arising from macroeconomic shocks, or systemic, arising from cascading failures due to interconnectedness. Interventions such as disease elimination and eradication (DEE) play a crucial role in mitigating the aggregate impact of such risks. However, conventional health economic evaluations often overlook these broader benefits realised during periods of instability, focusing instead on programme-specific risks under steady-state assumptions. Insights from financial economics can help capture this value and inform a more robust economic appraisal. This paper explores how concepts from financial economics can strengthen conventional health economic methods for evaluating programmes that reduce the aggregate impact of such system-level risks, using DEE as a primary example. It draws on asset pricing theory, macroeconomic models of rare disasters, real options analysis, and discounting practices. Key recommendations include recognising the added value of programmes that perform better during downturns due to the protection they offer against macroeconomic shocks or catastrophic events; using ‘real options’ thinking to manage uncertainty and preserve flexibility in long-term, high sunk cost projects; and accounting for equity considerations when setting discount rates for programmes with significant intergenerational impacts. The financial economics tools highlighted here could serve as key components of a broader analytical framework, supporting investment decisions that recognise and more accurately capture the value of investments that reduce the aggregate impact of system-level risks.Keywords
Funding Information
- Global Institute for Disease Elimination (Thanzi Labwino (Better Health))
This publication has 57 references indexed in Scilit:
- Concerning global rise in measles caseseClinicalMedicine, 2024
- Optimal timing of non-pharmaceutical interventions during an epidemicEuropean Journal of Operational Research, 2022
- Is systemic risk systematic? Evidence from the U.S. stock marketsInternational Journal of Finance & Economics, 2020
- Discounting in Economic EvaluationsPharmacoEconomics, 2018
- A real option analysis for stochastic disease control and vaccine stockpile policy: An application to H1N1 in KoreaEconomic Modelling, 2015
- Economic crisis and communicable disease control in Europe: A scoping study among national expertsHealth Policy, 2011
- Discounting, Preferences, and Paternalism in Cost-Effectiveness AnalysisHealth Care Analysis, 2011
- Discounting and decision making in the economic evaluation of health-care technologiesHealth Economics, 2010
- Investment in antiviral drugs: a real options approachHealth Economics, 2009
- An intertemporal asset pricing model with stochastic consumption and investment opportunitiesJournal of Financial Economics, 1979